Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.
暂无分享,去创建一个
Veronika Rockova | Bob Löwenberg | Bas J. Wouters | Ruud Delwel | V. Rocková | W. van Putten | B. Löwenberg | H. Beverloo | S. Abbas | B. Wouters | C. Erpelinck | R. Delwel | P. Valk | Peter J M Valk | Wim L J van Putten | Claudia A J Erpelinck | H Berna Beverloo | Bas J Wouters | Saman Abbas | V. Ročková | Claudia Erpelinck | Saman Abbas | Wim L. J. van Putten
[1] Torsten Haferlach,et al. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Gerhard Ehninger,et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.
[3] K. Döhner,et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. , 2006, Blood.
[4] J. Goeman. L1 Penalized Estimation in the Cox Proportional Hazards Model , 2009, Biometrical journal. Biometrische Zeitschrift.
[5] H. Kaneko,et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.
[6] P. Sonneveld,et al. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia , 1997, British journal of haematology.
[7] C. Bloomfield,et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. Hiddemann,et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Bas J. Wouters,et al. Brief Report Results and Discussion , 2022 .
[10] M. Caligiuri,et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Bolufer,et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. , 2004, Haematologica.
[12] B. Löwenberg,et al. Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[14] M. Levis,et al. FLT3: ITDoes matter in leukemia , 2003, Leukemia.
[15] High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome , 1997 .
[16] M. Caligiuri,et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Axel Benner,et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.
[18] Erdogan Taskesen,et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. , 2011, Blood.
[19] K. Döhner,et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Bob Löwenberg,et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.
[21] K. Tobal,et al. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia , 2003, British journal of haematology.
[22] R. Tibshirani. The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.
[23] K. Hornik,et al. Unbiased Recursive Partitioning: A Conditional Inference Framework , 2006 .
[24] K. Döhner,et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Augustin Ferrant,et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. , 2003, The New England journal of medicine.
[26] S. Fröhling,et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Naoe,et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. , 2004, Blood.
[28] R. Hills,et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[30] Stefan Fröhling,et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.
[31] C. Bloomfield,et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Bloomfield,et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. , 2008, Blood.
[33] J. Reilly,et al. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). , 2004, Haematologica.
[34] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[35] E. Hoster,et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Bas J. Wouters,et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling , 2009, Haematologica.
[37] T. Naoe,et al. Multiplex Real-time RT–PCR for Prospective Evaluation of WT1 and Fusion Gene Transcripts in Newly Diagnosed De Novo Acute Myeloid Leukemia , 2004, Leukemia & lymphoma.
[38] Y. Kanda,et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia , 2000, Cancer.
[39] K. Wagner,et al. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. , 2011, Blood.
[40] G. Peters,et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. , 2004, Blood.
[41] W. Hiddemann,et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.
[42] Bob Löwenberg,et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.
[43] U. Maurer,et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] A. Hagemeijer,et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] W. van Putten,et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. , 2010, Blood.
[46] J. Cayuela,et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.
[47] J. Reilly,et al. Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.
[48] M. Caligiuri,et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. , 2003, Blood.
[49] J. Griffin,et al. The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.
[50] M. Caligiuri,et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Bob Löwenberg,et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. , 2003, Blood.
[52] T. Pabst,et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis , 2009, British Journal of Cancer.
[53] B. Löwenberg,et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. , 2008, Blood.
[54] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[55] B. Falini,et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. , 2005, Blood.
[56] M A Boogaerts,et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.